RxDoctor Payments Data

Michael Wang, MD

Internal Medicine · Covina, CANPI 1588623045

Payments from drug & device makers

$6,938in general payments, 2019–2025

Across 32 payments — averaging $216.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Takeda Pharmaceuticals U.S.A., Inc.$6K
  • Spineology Inc.$698
  • Amgen$223
  • AbbVie$85
  • Bausch & Lomb Americas Inc.$82
  • AstraZeneca$80
  • plus $265 from 8 others

What the payments were for

  • Consulting fees$302%
  • Travel & lodging$69849%
  • Food & beverage$70549%

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,938 in reported general payments places this provider in the 90th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$137,347
Medicare patients
244
Services billed
1,251

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban147$130,226
JanuviaSitagliptin Phosphate58$63,880
FarxigaDapagliflozin Propanediol38$51,134
JardianceEmpagliflozin25$34,689
Trelegy ElliptaFluticasone/Umeclidin/Vilanter30$20,546
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr30$19,792
MyrbetriqMirabegron16$16,053
OzempicSemaglutide16$15,459
Spiriva HandihalerTiotropium Bromide12$10,242
NucyntaTapentadol Hcl11$8,118
Advair HfaFluticasone Propion/Salmeterol20$6,826
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog11$6,341
BrilintaTicagrelor11$6,264
Metoprolol Succinate263$5,618
Atorvastatin Calcium501$4,908

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Brilinta$80$57,39849 claims
GSKTrelegy Ellipta, Anoro Ellipta$79$40,33860 claims
Novo NordiskOzempic$61$15,45916 claims
AbbVieSynthroid$85$4,74471 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Covina

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →